Cargando…

Using the recurrence risk score by Joensuu to assess patients with gastrointestinal stromal tumor treated with adjuvant imatinib: A retrospective cohort study

In 2014, Joensuu and colleagues devised the first recurrence risk score (RRS) to identify the risk factors for gastrointestinal stromal tumor (GIST) recurrence. However, there are scarce data available on RRS effectiveness and efficiency. Therefore, we retrospectively analyzed clinical data to valid...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tang, Jianwei, Zhao, Rui, Zheng, Xiaobo, Xu, Liangliang, Wang, Yong, Feng, Lei, Ren, Shengsheng, Wang, Peng, Zhang, Ming, Xu, Mingqing
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Wolters Kluwer Health 2018
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6086542/ https://www.ncbi.nlm.nih.gov/pubmed/30024511 http://dx.doi.org/10.1097/MD.0000000000011400

Ejemplares similares

Risk factors for gastrointestinal stromal tumor recurrence in patients treated with adjuvant imatinib
por: Joensuu, Heikki, et al.
Publicado: (2014)

Neoadjuvant versus adjuvant imatinib in primary localized gastrointestinal stromal tumor
por: Ling, Jiayu, et al.
Publicado: (2023)

Optimizing Adherence to Adjuvant Imatinib in Gastrointestinal Stromal Tumor
por: Tetzlaff, Eric D., et al.
Publicado: (2013)

KIT and PDGFRA Variants and the Survival of Patients with Gastrointestinal Stromal Tumor Treated with Adjuvant Imatinib
por: Joensuu, Heikki
Publicado: (2023)

Adjuvant imatinib for patients with high-risk gastrointestinal stromal tumors: a retrospective cohort study
por: Zhao, Rui, et al.
Publicado: (2017)

Primary Prostatic Extra-Gastrointestinal Stromal Tumor Treated with Imatinib Mesylate as Neoadjuvant and Adjuvant Therapy: A Case Report and Literature Review
por: Shen, Haixiang, et al.
Publicado: (2019)

Adjuvant imatinib treatment improves recurrence-free survival in patients with high-risk gastrointestinal stromal tumours (GIST)
por: Nilsson, B, et al.
Publicado: (2007)

Reversible sarcopenia in patients with gastrointestinal stromal tumor treated with imatinib
por: Moryoussef, Frédérick, et al.
Publicado: (2015)

KIT and PDGFRA Mutations and Survival of Gastrointestinal Stromal Tumor Patients Treated with Adjuvant Imatinib in a Randomized Trial
por: Joensuu, Heikki, et al.
Publicado: (2023)

Impact of adjuvant imatinib on bone and muscle density in patients with resected gastrointestinal stromal tumors
por: Fulgenzi, Claudia Angela Maria, et al.
Publicado: (2022)

Response to imatinib rechallenge in a patient with a recurrent gastrointestinal stromal tumor after adjuvant therapy: a case report
por: Kang, Yoon-Koo
Publicado: (2011)

Long-term adjuvant imatinib treatment for a patient who underwent complete resection of a localized recurrent gastrointestinal stromal tumor after preoperative imatinib treatment: A case report
por: Tjhoi, Welda E.H., et al.
Publicado: (2019)

Preoperative imatinib for patients with primary unresectable or metastatic/recurrent gastrointestinal stromal tumor
por: Shen, Chaoyong, et al.
Publicado: (2014)

Recent Advancements in the Treatment of Rectal Gastrointestinal Stromal Tumor: In Era of Imatinib
por: Qu, Hui, et al.
Publicado: (2022)

Long-term Results of Adjuvant Imatinib Treatment for Localized Gastrointestinal Stromal Tumors after Surgery
por: Aznab, Mozaffar, et al.
Publicado: (2018)

Postoperative Adjuvant Imatinib Therapy-Associated Nomogram to Predict Overall Survival of Gastrointestinal Stromal Tumor
por: Liu, Xuechao, et al.
Publicado: (2022)

Imatinib treatment for gastrointestinal stromal tumour (GIST)
por: Lopes, Lisandro F, et al.
Publicado: (2010)

Cost-utility analysis of adjuvant imatinib treatment in patients with high risk of recurrence after gastrointestinal stromal tumour (GIST) resection in Thailand
por: Bussabawalai, Thanaporn, et al.
Publicado: (2019)

Hepatitis B Virus Reactivation in Gastrointestinal Stromal Tumor Patients Treated With Imatinib
por: Lei, Tianxiang, et al.
Publicado: (2021)

Metachronous Primary Adenocarcinoma of Lung During Adjuvant Imatinib Mesylate Therapy for Gastrointestinal Stromal Tumor of Stomach: A Case Report
por: Jiang, Meng-jie, et al.
Publicado: (2015)

Primary hepatic gastrointestinal stromal tumor with right adrenal gland invasion: A case report and systematic literature review
por: Xu, Liangliang, et al.
Publicado: (2019)

Recurrent Gastrointestinal Stromal Tumors in the Imatinib Mesylate Era: Treatment Strategies for an Incurable Disease
por: Platoff, Rebecca M., et al.
Publicado: (2017)

Identification of Novel Imatinib-Resistant Genes in Gastrointestinal Stromal Tumors
por: Cao, Lei, et al.
Publicado: (2022)

Imatinib-induced podocytopathies in a patient with gastrointestinal stromal tumor
por: Wang, Gang, et al.
Publicado: (2021)

Treatment of gastrointestinal stromal tumor: focus on imatinib mesylate
por: Din, Omar S, et al.
Publicado: (2008)

Update on imatinib for gastrointestinal stromal tumors: duration of treatment
por: Linch, Mark, et al.
Publicado: (2013)

Overcoming heterogenity in imatinib-resistant gastrointestinal stromal tumor
por: Serrano, César, et al.
Publicado: (2019)

Cystic Changes in Intraabdominal Extrahepatic Metastases from Gastrointestinal Stromal Tumors Treated with Imatinib
por: Kim, Hyo-Cheol, et al.
Publicado: (2004)

GASTROINTESTINAL STROMAL TUMOR OF THE RECTUM TREATED WITH NEOADJUVANT IMATINIB FOLLOWED BY TRANSANAL ENDOSCOPIC MICROSURGERY
por: NAHAS, Caio Sergio Rizkallah, et al.
Publicado: (2015)

Imatinib-induced hepatitis treated by corticosteroids in a patient with metastatic gastrointestinal stromal tumor
por: Kang, Min Kyu, et al.
Publicado: (2019)

Gastrointestinal stromal tumor (GIST) recurrence following surgery: review of the clinical utility of imatinib treatment
por: Deshaies, Isabelle, et al.
Publicado: (2010)

Personalized Dose of Adjuvant Imatinib in Patients with Gastrointestinal Stromal Tumors: Results from a Population Pharmacokinetic Analysis
por: Jiang, Xuehui, et al.
Publicado: (2023)

Feasibility and Timing of Cytoreduction Surgery in Advanced (Metastatic or Recurrent) Gastrointestinal Stromal Tumors During the Era of Imatinib
por: Chang, Shih-Chun, et al.
Publicado: (2016)

Impact of Rechallenge with Imatinib in Patients with Advanced Gastrointestinal Stromal Tumor after Failure of Imatinib and Sunitinib
por: Sawaki, Akira, et al.
Publicado: (2014)

Imatinib rechallenge in patients with advanced gastrointestinal stromal tumors following progression with imatinib, sunitinib and regorafenib
por: Vincenzi, Bruno, et al.
Publicado: (2018)

Advances in the research of the mechanism of secondary resistance to imatinib in gastrointestinal stromal tumors
por: Hu, Xiangchen, et al.
Publicado: (2022)

Imatinib in gastrointestinal stromal tumour: Northern Cancer Network experience
por: Azribi, F, et al.
Publicado: (2009)

Update on the treatment of gastrointestinal stromal tumors (GISTs): role of imatinib
por: Quek, Richard, et al.
Publicado: (2010)

ZNF-Mediated Resistance to Imatinib Mesylate in Gastrointestinal Stromal Tumor
por: Rink, Lori, et al.
Publicado: (2013)

Optimizing Surgical and Imatinib Therapy for the Treatment of Gastrointestinal Stromal Tumors
por: Sicklick, Jason K., et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_1j7b6p7stbgc4bo7fhdcr5m846